NCT04623216 2025-10-16
Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.
Novartis
Phase 1/2 Terminated
Clinical Trials
8 trialsNCT04506086 2025-05-18
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 4 Terminated
NCT03038230 2025-04-06
MCLA-117 in Acute Myelogenous Leukemia
Merus B.V.
Phase 1 Terminated
NCT04310592 2024-12-12
CYNK001AML01
Celularity Incorporated
Phase 1 Terminated
NCT04545333 2024-08-01
The clonoSEQ® Watch Registry
Adaptive Biotechnologies
Terminated
NCT04748848 2023-03-02
A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
Celgene
Phase 1 Terminated
NCT03441464 2022-02-25
Feasibility of the LUM Imaging System for Detection of Prostate Cancer
Lumicell, Inc.
Phase 1/2 Terminated
NCT00172068 2009-12-23
MRD-1
Novartis
Phase 2 Terminated